AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.
Source link
Trending
- A single cobalt shock could trigger global EV battery supply chaos
- AbbVie in Talks to Buy Apogee Therapeutics for USD 10.9 Billion
- Founders Fund’s outlier bet on humanely killed fish
- Affordable housing, rental expansion and RERA reforms set to define next growth phase in India’s urban region: Report
- We read the Social Security and Medicare trustees reports. If you’re not worried, you should be.
- Lebanese turtle conservationist Mona Khalil killed by Israeli strike
- ‘On his way back’: Sena (UBT) hopeful rebel MP Nimbalkar may not defect | India News
- AEW Star Misses Scheduled Event; Provides An Explanation
